These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 27498850)

  • 1. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Buisan O; Orsola A; Areal J; Font A; Oliveira M; Martinez R; Ibarz L
    Clin Genitourin Cancer; 2017 Feb; 15(1):145-151.e2. PubMed ID: 27364982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.
    Seah JA; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Knox JJ; Joshua AM; Sridhar SS
    Clin Genitourin Cancer; 2015 Aug; 13(4):e229-e233. PubMed ID: 25777682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.
    Buisan O; Orsola A; Oliveira M; Martinez R; Etxaniz O; Areal J; Ibarz L
    Clin Genitourin Cancer; 2017 Aug; 15(4):e697-e706. PubMed ID: 28274590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
    Black AJ; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand S; Sridhar SS; Black PC
    Urol Oncol; 2020 Jan; 38(1):3.e17-3.e27. PubMed ID: 31676278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
    Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
    Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer.
    Mendoza-Valderrey A; Choe J; Kessler DM; Jimenez G; Li X; Kolker S; Allen W; Linehan JA; Twardowski PW; Ascierto ML
    Cancer Med; 2024 Aug; 13(15):e70088. PubMed ID: 39119802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Mansour AM; Soloway MS; Eldefrawy A; Singal R; Joshi S; Manoharan M
    Can J Urol; 2015 Apr; 22(2):7690-7. PubMed ID: 25891331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
    Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological response and survival outcomes after neoadjuvant chemotherapy with radical cystectomy in octogenarians for muscle-invasive bladder cancer: an observational database study.
    Avudaiappan AP; Prabhakar P; Sandman MS; Rubens M; Garje R; Eldefrawy A; Manoharan M
    BMC Urol; 2024 Jul; 24(1):150. PubMed ID: 39049001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
    Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
    Rose TL; Deal AM; Basch E; Godley PA; Rathmell WK; Kim WY; Whang YE; Dunn MW; Wang A; Chen RC; Nielsen ME; Pruthi RS; Wallen EM; Woods ME; Smith AB; Milowsky MI
    Urol Oncol; 2015 Sep; 33(9):386.e1-6. PubMed ID: 26122712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.